Search research articles
Contact Us
Filters
Showing results (341-350 of 444) with videos related to
Page
of 45
Sort By:
JCO Precision Oncology
|
October 15, 2021
Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an <i>NTRK2</i> Fusion: The Impact of Integrated Genomic Profiling
Ross Mangum, Jacquelyn Reuther, Kelsey C Bertrand, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2018
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
Jonathan W Riess, David R Gandara, Garrett M Frampton, et al.
Nature Communications
|
February 8, 2017
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome
Andrea J Cohen, Alina Saiakhova, Olivia Corradin, et al.
Nature
|
July 31, 2024
Histone serotonylation regulates ependymoma tumorigenesis
Hsiao-Chi Chen, Peihao He, Malcolm McDonald, et al.
Cell
|
November 26, 2019
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
Andrew R Morton, Nergiz Dogan-Artun, Zachary J Faber, et al.
Cancer Research
|
July 22, 2017
MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells
Xiuxing Wang, Zhi Huang, Qiulian Wu, et al.
Science Translational Medicine
|
August 9, 2019
Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells
Xiuxing Wang, Kailin Yang, Qiulian Wu, et al.
International Journal of Cancer
|
September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial
Amir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.
Molecular Cancer Therapeutics
|
February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Nicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Page
of 45
Search research articles
Search
Showing results (341-350 of 444) with videos related to
Sort By:
Page
of 45
JCO Precision Oncology
|
October 15, 2021
Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an <i>NTRK2</i> Fusion: The Impact of Integrated Genomic Profiling
Ross Mangum, Jacquelyn Reuther, Kelsey C Bertrand, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2018
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
Jonathan W Riess, David R Gandara, Garrett M Frampton, et al.
Nature Communications
|
February 8, 2017
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome
Andrea J Cohen, Alina Saiakhova, Olivia Corradin, et al.
Nature
|
July 31, 2024
Histone serotonylation regulates ependymoma tumorigenesis
Hsiao-Chi Chen, Peihao He, Malcolm McDonald, et al.
Cell
|
November 26, 2019
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
Andrew R Morton, Nergiz Dogan-Artun, Zachary J Faber, et al.
Cancer Research
|
July 22, 2017
MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells
Xiuxing Wang, Zhi Huang, Qiulian Wu, et al.
Science Translational Medicine
|
August 9, 2019
Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells
Xiuxing Wang, Kailin Yang, Qiulian Wu, et al.
International Journal of Cancer
|
September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial
Amir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.
Molecular Cancer Therapeutics
|
February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Nicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Page
of 45